OctoPlus wins drug development and manufacturing contract from Danish pharmaceutical company

OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), announces today that a process development and manufacturing contract has been signed with a pharmaceutical company headquartered in Denmark. The undisclosed contract value will make a material contribution to OctoPlus' annual revenues.
Under the contract terms, we will perform process development and manufacturing of a microsphere-based formulation for our client.
At OctoPlus we provide formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. In addition to our expertise in formulation and manufacturing, we offer our clients drug delivery technologies for the development of controlled release versions of existing or new drugs.

OctoPlus Wins Drug Development Contract From Global Pharmaceutical Company

OctoPlus N.V. ("OctoPlus" or the "Company") , announces today that it has signed a pharmaceutical development contract with an undisclosed global pharmaceutical company. The undisclosed contract value will make a material contribution to OctoPlus' annual revenues.

Under the contract terms, OctoPlus will perform formulation development for the client's product candidate.

OctoPlus provides formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. In addition to its expertise in formulation and manufacturing, OctoPlus offers its clients drug delivery technologies for the development of controlled release versions of existing or new drugs.

For further information, please contact: Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071 or send an e-mail to Investor Relations at IR@octoplus.nl.

About OctoPlus OctoPlus is a drug delivery company committed to the creation of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.